期刊文献+

国产格列美脲对2型糖尿病胰岛分泌功能及胰岛素敏感性的影响 被引量:1

下载PDF
导出
摘要 目的 :探讨国产格列美脲对 2型糖尿病 (DM)病人的胰岛素分泌功能和胰岛素敏感性的影响。方法 :对按 1 998年 WHO诊断标准判定的 2型 DM病人 2 9例 ,给予国产格列美脲片 2~ 6 m g/ d,疗程 8周 ,治疗前后测定空腹血糖 (FBS) ,餐后 2 h血糖 (PBS) ,空腹胰岛素 (FINS)、餐后胰岛素 (PINS)、糖化血红蛋白 (Hb A1 c)、按胰岛素抵抗稳态模型公式 :FINS× FBS/ 2 2 .5计算出胰岛素抵抗指数 (IRI)。结果 :经治疗 8周 ,FBS降低 (1 .4 2± 1 .6 0 ) mm ol/ L (P <0 .0 0 1 ) ,PBS降低 (3.2 5± 2 .97) mmol/ L(P <0 .0 0 1 ) ,FINS无明显改变 (P >0 .0 0 5 ) ,PINS增加 (33.96± 1 9.4 6 ) m IU / L (P <0 .0 0 1 ) ;IRI为 1 .5 2± 0 .4 7,较治疗前明显降低 (P <0 .0 0 1 )。结论 :国产格列美脲可以在刺激
出处 《广西医科大学学报》 CAS 2003年第6期892-893,共2页 Journal of Guangxi Medical University
  • 相关文献

参考文献7

  • 1[1]Cambell RK.Glimepiride:Role of new sulfonylurea in the treatment of type 2 diabetes mellitus.Ann Pharmacother,1998,32:1 044.
  • 2[2]Haffner SM,Gonzalez C,Mietnen H,et al.A prospective analysis of the HOMA model.The Mexico City Diabetes Study.Diabtes Care,1997,20:1 138-1 141.
  • 3[3]Korytkowski M,Thoms A,Reid L,et al.Glimepiride improves both first and second phase of insulin secretion in type 2 diabetes.Diabetes Care,2002,25(9):1 607-1 611.
  • 4[4]Rosak C.The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.J Diabetes Complication,2002,16(1):123-132.
  • 5陈亮,杨华章,陈红梅,陈重,廖晓征,崔炎棠.格列美脲对代谢综合征中糖尿病患者的疗效观察[J].中国实用内科杂志,2003,23(1):63-63. 被引量:2
  • 6李启富.新型磺脲药格列美脲[J].辽宁实用糖尿病杂志,2000,8(4):48-49. 被引量:4
  • 7[7]Muller G,Hartz D,Punter J,et al.Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor.I.Binding Characteristics.Biochim Biophys Acta,1994,1191:267.

二级参考文献9

  • 1[1]Alberti KGMM, Zimmet PZ.For the WHO Consultation:definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation.Diabetes Med,1998, 15: 539~553
  • 2Campbell RK. Glimepiride: Role of a new suffonylurea in the treatnent of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044.
  • 3Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994; 1191: 267.
  • 4Schade DS, Jovanovic - Peterson L, Schneider J. A phacebo- controlled dose - titration study of glimepiride in patients with non - insulin - dependent diabetes mellitus (NIDDM).Hoechst Marion Roussel Inc., 1997.
  • 5Sonenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, et al. Shortterm comparison of once - versus twice- daily administration of glimepiride in patients with non - insulin- dependent diabetes mellitus. Ann Pharmacother 1997; 31:671.
  • 6Goldberg RB, Holvey SM, Schneider J, The Glimepiride Protocol# 201 Study Group. A dose response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996; 19: 847.
  • 7Dills DG, Schneider J, The Glimepiride/Glyburide Study Group. Clinical evaluation of glimepiride versus glyburied in NIDDM in a double - bline comparative study. Horm Metah Res 1996;28:426.
  • 8Clark CM, Goldberg RB. Glimepiride dosing and efficacy;results of pacebo - controlled, dose - regimen, and active - controlled triabls. In: White - house F, Gavin J, eds. Postgraduate medicine special reprot: therapeutic strategies for managing NIDDM. Minneapolis: McGraw - Hill Healthcare Information Group,June 1997;45.
  • 9Schneider J, Chaikin P, limepiride safety. Results of placebo- con - trolled, dose - regimen, and active - controlled trials.In:Whitehouse F, Gavin J, eds. Postgraduate medicine special report: therapeutic strategies for managing NIDDm. Minneapolis:McGraw - Hill Healthcare Information Group, June 1997 ;33.

共引文献3

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部